MICHR K Award
Mentored Clinical Scientists Career Development (MICHR K) award is a two-year award to provide protected time for a clinician scientist to focus on conducting clinical research. The program is supported by a combination of funds from MICHR and the candidate's base department. The faculty lead for this program is Vicki Ellingrod, PharmD, BCPP, FCCP.
Click here for frequently asked questions.
The application deadline is March 1, 2016, with letter of intent due December 13, 2015. Submit your letter of intent.
The program runs 2 years, beginning June 1.
Please apply for the MICHR K Award through the Competition Space website.
75% (50% for surgical subspecialties) protected time
Salary for protected time cost-shared (37.5% from MICHR and 37.5% from their base department)
$25,000 for research costs and $5,000 for tuition expenses annually
"It provides a great stepping stone to establishing your research career and the opportunity to work with mentors to develop your science."
-Madhuri Kakarala, MD, PhD, RD
MICHR K Scholars have:
- Access to seminars and workshops in clinical and translational research methodology
- Access to the MICHR Post-doctoral Career Development Seminar
- Assistance in the selection of appropriate specialized courses
- Guidance for the trainee’s scientific research from a multidisciplinary mentoring team
- Individualized career development guidance from MICHR faculty
- Consultation with MICHR professional staff on clinical research conduct and grant proposal development, including the scholars' own K-series award
- National exposure through participation in the Association of Clinical and Translational Science (ACTS) annual meeting in Washington, D.C.
Who is eligible?
To ensure that applicants prepare competitive proposals, candidates are strongly encouraged to contact us as soon as they decide to apply for the MICHR K
Eligible applicants hold an MD or PhD with a clinical or health focus
University of Michigan junior faculty and mid-career health care professionals initiating careers in clinical research are encouraged to apply
Candidates must be nominated and obtain a funding commitment by their department chair and display clear potential for academic success
Candidates must be U.S. citizens or U.S. permanent resident
Applications follow the K23 application format and require:
A plan for training and career development
A clinical research proposal intended to lead to future clinical trials
A description of a strong mentoring arrangement
A specific budget with budget justification
Our 2015 MICHR K Cohort:
|Daniel Hertz, PhD (Pharmacy) is developing and translating novel approaches to individualize cancer treatment. In this study he is discovering clinically useful predictors of paclitaxel-induced peripheral neuropathy in breast cancer patients. The primary objective is to identify a maximum-tolerated paclitaxel exposure to prospectively test whether individualized dosing improves efficacy while minimizing toxicity. If successful, this individualized dosing approach could be applied to other chemotherapeutic agents to optimize therapeutic outcomes. Additionally, he will investigate a novel framework for discovering pharmacogenomic predictors of treatment-related toxicities that could enable identification of patients that are highly sensitive to toxicity, for further treatment individualization. Mentors: N. Lynn Henry (Hematology/Oncology), James Rae (Pharmacology), and Duxin Sun (Pharmaceutical Sciences).
|Laura Mariani, MD MS (Internal Medicine, Nephrology) has a clinical and research interest in primary glomerular disease, rare kidney diseases which can have dramatic patient variability in response to therapy and prognosis. Her study will leverage gene expression data from kidney biopsy tissue to identify subgroups of patients who share common underlying disease mechanisms. The ultimate goal of this approach is to be able to better inform treatment decisions by combining clinical characteristics, molecular features and biomarker results to implement precision medicine for patients with these potentially devastating diseases. Mentors: Bruce Robinson, MD (Arbor Research Collaborative for Health and UM Nephrology) and Matthias Kretzler, MD (Nephrology).
Call or email:
Vicki Ellingrod, PharmD, BCPP, FCCP
(College of Pharmacy)
Lise Anderson, MPH
Feedback on this page? Email Brandon Lynn